Clinical Trials on HR-positive,HER2-negative in Advanced Breast Cancer in Singapore
Total 16 results
-
National Cancer Centre, SingaporeMSD Pharma (Singapore) Pte LtdRecruitingHormone Receptor-Positive HER2-Negative Advanced Breast CancerSingapore
-
National University Hospital, SingaporeAdagene IncActive, not recruitingAdvanced Solid Tumor | HER2-negative Breast CancerSingapore
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
National University Hospital, SingaporeRecruitingAdvanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast CancersSingapore
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast CancerFrance, Italy, Germany, Singapore, Sweden, Spain, United Kingdom, United States
-
National University Hospital, SingaporeMerck Sharp & Dohme LLC; Adagene IncRecruitingTriple Negative Breast Cancer | Advanced Solid TumorSingapore
-
University of MalayaNational University Hospital, Singapore; Merck Sharp & Dohme LLC; Cancer Research...RecruitingHER2-Negative Breast CancerSingapore, Malaysia
-
National Cancer Centre, SingaporeCompletedHER 2 Positive Advanced Gastric CancerSingapore
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Novartis PharmaceuticalsActive, not recruitingAdvanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part SarcomaUnited States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France